share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director ANDO GORAN

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director ANDO GORAN

EyePoint Pharmaceuticals | 4：持股變動聲明-董事 ANDO GORAN
美股SEC公告 ·  08/22 04:06
牛牛AI助理已提取核心訊息
Goran Ando, associated with EyePoint Pharmaceuticals, Inc. (EYPT), executed a purchase of 5,000 shares of common stock on August 21, 2024. The transaction was carried out on the open market at a price of $7.95 per share. Following this acquisition, Ando's direct holdings in the company increased to 13,150 shares. The transaction is currently reported as in progress.
Goran Ando, associated with EyePoint Pharmaceuticals, Inc. (EYPT), executed a purchase of 5,000 shares of common stock on August 21, 2024. The transaction was carried out on the open market at a price of $7.95 per share. Following this acquisition, Ando's direct holdings in the company increased to 13,150 shares. The transaction is currently reported as in progress.
Goran Ando，與EyePoint Pharmaceuticals，Inc.（EYPT）相關，於2024年8月21日購買了5000股普通股。該交易是在開放市場上以每股7.95美元的價格進行的。在此次收購之後，Ando在公司的直接持股增加到13,150股。該交易目前被報告爲正在進行中。
Goran Ando，與EyePoint Pharmaceuticals，Inc.（EYPT）相關，於2024年8月21日購買了5000股普通股。該交易是在開放市場上以每股7.95美元的價格進行的。在此次收購之後，Ando在公司的直接持股增加到13,150股。該交易目前被報告爲正在進行中。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間